TIGIT-based immunotherapeutics in lung cancer

Akshay J Patel; Gary W Middleton

doi:10.1093/immadv/ltad009

TIGIT-based immunotherapeutics in lung cancer

Immunother Adv. 2023 May 26;3(1):ltad009. doi: 10.1093/immadv/ltad009. eCollection 2023.

Authors

Akshay J Patel^{1

2}, Gary W Middleton^{1

3}

Affiliations

¹ Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
² Department of Thoracic Surgery, University Hospitals Birmingham, Birmingham, UK.
³ Department of Medical Oncology, University Hospitals Birmingham, Birmingham, UK.

Abstract

In this review, we explore the biology of the TIGIT checkpoint and its potential as a therapeutic target in lung cancer. We briefly review a highly selected set of clinical trials that have reported or are currently recruiting in non-small cell and small cell lung cancer, a disease transformed by the advent of PD-1/PD-L1 checkpoint blockade immunotherapy. We explore the murine data underlying TIGIT blockade and further explore the reliance of effective anti-TIGIT therapy on DNAM-1(CD226)-positive activated effector CD8+ T cells. The synergism with anti-PD-1 therapy is also explored. Future directions in the realm of overcoming resistance to checkpoint blockade and extending the repertoire of other checkpoints are also briefly explored.

Keywords: TIGIT; immunotherapy; lung cancer; non-small cell lung cancer; small cell lung cancer.

Publication types

Review